Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window

Stock News

UNH Stock Surges: Time to Buy?

Matt MonacoAvatar
Written by Matt Monaco
Updated 8/15/2025, 9:19 am ET | 6 min

In this article Last trade Aug, 15 7:44 PM

  • UNH+12.81%
    UNH - NYSEUnitedHealth Group Incorporated (DE)
    $306.28+34.79 (+12.81%)
    Volume:  73.84M
    Float:  904.60M
    $294.71Day Low/High$310.30

UnitedHealth Group Incorporated (DE) stocks have been trading up by 11.56 percent amid rising market optimism.

Candlestick Chart

Live Update At 09:19:09 EST: On Friday, August 15, 2025 UnitedHealth Group Incorporated (DE) stock [NYSE: UNH] is trending up by 11.56%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

UnitedHealth’s Recent Financials: A Quick Overview

When it comes to successful trading, it’s essential to keep a long-term perspective rather than constantly seeking quick wins. As millionaire penny stock trader and teacher Tim Sykes says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.” This approach encourages traders to focus on consistent improvements and disciplined strategies that compound over the long run. By prioritizing steady growth, traders can avoid the pitfalls of high-risk moves and instead cultivate a stable and profitable trading journey.

UnitedHealth Group, a name synonymous with innovation and growth, has showcased robustness in its recent financial results. It’s not just about numbers, but how those numbers paint a broader picture of stability and potential in a fluctuating market. With an impressive net income from continuing operations at around $3.57 billion, UnitedHealth has laid strong foundations for future growth. Despite being a giant with towering revenues of approximately $111.62 billion, what’s fascinating is their approach in streamlining expenses, maintaining a net income of about $3.4 billion.

This comes alongside a high earnings before interest, taxes, depreciation, and amortization (EBITDA) of $6.19 billion, reflecting the strength in their core operations. Their ability to manage long-term debts judiciously, standing at about $73.49 billion, and the maintenance of a leverage ratio of 3.3 offer investors insights into their strategic decisions. With the announcement of a regular dividend rate at $2.21 per share, UnitedHealth confirms its strategy to reward faithful shareholders, a happy occurrence for those who favor dividend-focused investments.

The market’s response to UnitedHealth’s strategic maneuvers, such as the acquisition of Amedisys, is interestingly correlated with the recent adjustments in target prices by several financial institutions. While firms like Bernstein and Wells Fargo may have adjusted their price expectations, the overarching sentiment leans toward optimism as UnitedHealth persistently conquers regulatory hindrances and adapts to climactic market waves.

Delving Into The News: Impacts and Analyses

Recent star-studded investments by Berkshire Hathaway, famously captained by Warren Buffett, in UnitedHealth prompt a 7% climb in shares during after-hours trading. Such moves echo a strong vote of confidence from one of the most revered investors. The decision aligns with the macro trend of institutions opting for rock-solid, enduring growth entities in times marked by economic volatility.

Amedisys, now under the belt of UnitedHealth, enhances its footprint in home health and hospice care, amid a landscape where healthcare needs are more underscored than ever. This acquisition reflects UnitedHealth’s strategic positioning, capturing growth segments that are anticipated to boom as the healthcare industry continues its dynamic evolution.

Interestingly, investment firms such as Lone Pine Capital and Scion Asset Management have endured the temptation to add UnitedHealth to their portfolios, a strategy that resonates well with their forward-looking approach. Simultaneously, the market observes the NBA-style trading of stocks where one team’s roster change, in this case, S&P MidCap 400’s, significantly affects team dynamics, ushering in Twilio as Amedisys exits its ranks.

Perhaps, what serves as a powerful narrative is the Justice Department’s regulatory settlements with UnitedHealth. The green-lighting of the Amedisys acquisition marks more than just a strategic victory. It’s a premeditated stride towards embracing innovation while responsibly tackling regulatory challenges. Such prudent maneuvers not only clear paths for business integrations but also capture market optimism.

More Breaking News

Financial Storytelling: The Untold and The Understood

UnitedHealth’s journey is a gripping narrative of how a corporation steers through the labyrinth of acquisitions, regulatory landscapes, and market expectations. The reflection of its financial metrics, with potent profitability ratios such as a profit margin of approximately 5.57% and a return on equity nearing 24.33%, establishes a story of effectiveness in monetary stewardship.

Looking at their operational movements, it comes as no surprise that the stock market recognizes the prowess behind UnitedHealth’s global strategy; increasing asset turnover to 1.4 signals that they’re extracting more value from every dollar invested in assets. The market, essentially hungry for securities that cater to not just present yields but future growth, finds a notable resonation with UnitedHealth’s forward yield of around 3.26%. As millionaire penny stock trader and teacher Tim Sykes, says, “You must adapt to the market; the market will not adapt to you.” UnitedHealth demonstrates an astute awareness of this trading wisdom by continually evolving its strategies to meet emerging market demands.

Bringing this narrative full circle, external trading dialogues—whether it’s Berkshire Hathaway’s substantial stake or Wallstreet ops influencing premarket varieties—highlight a singular trend: market faith in stalwarts capable of harnessing both tradition and innovation. UnitedHealth personifies this dynamic tension, creating value-driven pathways that cater not only to the immediate gratification of earnings but to sustained shareholder wealth over time.

In sum, UnitedHealth’s current financial trajectory, powered by robust strategic initiatives and astute financial handling, forms the backbone of its market ascension. Such moves do not just bolster the present stock prices but, harmoniously with projected innovations, craft a lasting legacy.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:


How much has this post helped you?



Leave a reply

Author card Timothy Sykes picture

Matt Monaco

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
He is a diligent trader and teacher in his To The Moon Report blogs and Small Cap Rockets strategy webinars. He shows up every day, and expects his students to as well. Matt is fond of trading sketchy, volatile OTC stocks with profit potential. His favorite patterns are panic dip buys and breakouts.
Read More

In this article (YTD Performance)


* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM
notification icon
Subscribe to receive notifications